Arcadia biosciences, inc. (RKDA)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Revenues:
Total revenues

1,320

1,169

1,197

1,175

1,408

1,464

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating expenses (income):
Total revenues

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Product

-

-

-

-

-

-

-

-

-

-

-

-

619

669

505

526

640

466

472

416

302

355

0

0

0

License

-

-

-

-

-

-

-

-

-

-

-

-

98

144

953

949

1,210

1,216

2,636

2,513

2,307

2,325

0

0

0

Contract research and government grants

-

-

-

-

-

-

-

-

-

-

-

-

2,637

2,375

2,536

3,267

3,601

3,732

3,758

3,616

3,811

4,302

0

0

0

Total revenues

-

-

-

-

-

-

-

-

-

-

-

-

3,354

3,188

3,994

4,742

5,451

5,414

6,866

6,545

6,420

6,982

0

0

0

Operating expenses:
Cost of product revenues

-

-

-

-

-

-

-

-

-

-

-

-

854

895

911

912

983

892

288

2,022

1,962

1,997

0

0

0

Research and development

7,837

7,098

6,931

6,334

6,178

6,069

6,690

7,105

6,980

7,407

7,231

7,737

8,284

8,663

8,542

9,466

9,336

8,966

9,167

9,672

9,861

10,012

0

0

0

Selling, general and administrative

14,478

13,567

13,457

11,991

11,795

11,604

10,822

10,226

10,220

10,651

11,778

12,050

11,866

12,250

11,760

11,891

11,917

11,119

10,533

9,681

10,879

10,126

0

0

0

Total operating expenses

22,273

20,550

20,943

18,827

18,657

18,334

17,964

17,699

17,413

18,341

19,924

20,722

21,004

21,808

21,213

22,269

22,236

20,977

19,988

21,375

22,702

22,135

0

0

0

Loss from operations

-20,953

-19,381

-19,746

-17,652

-17,249

-16,870

-15,516

-15,032

-14,191

-14,315

-16,786

-17,098

-17,650

-18,620

-17,219

-17,527

-16,785

-15,563

-13,122

-14,830

-16,282

-15,153

0

0

0

Interest expense

0

-

0

-

-

-

-

-

-

747

1,081

1,369

1,331

1,319

1,635

2,070

2,518

2,658

2,354

1,853

1,477

1,394

0

0

0

Other income, net

418

466

468

483

476

394

301

213

223

281

344

388

360

340

1,139

1,334

1,993

521

-361

-1,459

-1,972

-597

0

0

0

Initial loss on common stock warrant and common stock adjustment feature liabilities

-

-

-

-

-

4,000

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of common stock warrant liabilities

-7,413

9,243

3,215

-12,983

-2,966

-9,561

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Offering costs

-

-

0

0

-

2,555

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on extinguishment of debt

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net income (loss) before income taxes

-13,838

-28,871

-23,208

-4,563

-15,458

-13,470

0

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss before income taxes

-

-

-

-

-

-

-

-

-

-

-

-18,079

-18,621

-19,599

-17,945

-18,493

-17,540

-17,930

0

0

0

-

-

-

-

Net loss before income taxes and equity in loss of unconsolidated entity

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-17,144

0

0

0

Income tax provision

0

2

-1

7

19

10

21

29

26

26

32

26

29

25

-172

-276

-197

26

250

390

399

263

0

0

0

Net income (loss)

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss attributable to non-controlling interest

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Equity in loss of unconsolidated entity

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-932

0

0

0

Net income (loss) attributable to common stockholders

-13,668

-28,805

-23,207

-4,570

-15,477

-13,480

-15,794

-24,769

-22,106

-15,707

-18,455

-18,105

-18,650

-19,624

-17,773

-18,217

-17,343

-17,956

-16,087

-18,532

-20,666

-18,339

0

0

0

Accretion of redeemable convertible preferred stock to redemption value

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,574

4,144

4,662

0

-

0

0

-

Deemed dividends to warrant holder

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

197

0

0

0

-

-

-

-

Net loss attributable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-20,727

-20,508

-24,523

-26,296

-22,077

0

0

0

Net income (loss) per share attributable to common stockholders:
Basic and diluted

0.29

-0.69

-2.04

0.84

-2.64

2.37

0.93

-2.02

-4.86

-1.38

-2.12

-1.88

-1.90

-8.54

-0.09

-0.10

-0.12

3.28

-0.11

-0.19

-3.71

-1.75

-4.19

-3.08

-1.69

Weighted-average number of shares used in per share calculations:
Basic

8,651

-

-

-

4,776

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Diluted

8,674

-

-

-

4,776

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Basic and diluted

-

-

6,942

5,054

-

4,797

4,774

3,307

2,186

2,139

2,133

2,133

2,218

-124,020

44,370

44,308

44,215

44,738

43,647

23,775

2,075

2,070

2,061

2,056

2,056

Other comprehensive loss, net of tax
Unrealized losses on available-for-sale securities

0

-

0

-

-

-

3

13

20

18

2

-7

11

96

0

0

0

-

-

-

-

-

-

-

-

Other comprehensive loss

0

-

0

-

-

-

3

13

20

18

2

-7

11

96

0

0

0

-

-

-

-

-

-

-

-

Comprehensive income (loss) attributable to common stockholders

-13,668

-28,804

-23,207

-4,571

-15,478

-13,480

-15,791

-24,756

-22,086

-15,689

-18,453

-18,112

-18,639

-19,528

-17,780

-18,223

-18,253

-20,842

0

0

0

-

-

-

-

Product
Total revenues

861

814

749

677

703

657

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cost of product revenues

958

885

555

502

684

661

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

License
Total revenues

0

-

0

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Royalty
Total revenues

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Contract Research And Government Grants
Total revenues

262

288

381

438

555

657

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-